BR112014019672A8 - Triterpenoides de c-3 cicloalquenila com atividade inibidora de maturação de hiv - Google Patents

Triterpenoides de c-3 cicloalquenila com atividade inibidora de maturação de hiv

Info

Publication number
BR112014019672A8
BR112014019672A8 BR112014019672A BR112014019672A BR112014019672A8 BR 112014019672 A8 BR112014019672 A8 BR 112014019672A8 BR 112014019672 A BR112014019672 A BR 112014019672A BR 112014019672 A BR112014019672 A BR 112014019672A BR 112014019672 A8 BR112014019672 A8 BR 112014019672A8
Authority
BR
Brazil
Prior art keywords
cycloalkenyl
inhibitory activity
hiv maturation
triterpenoids
compounds
Prior art date
Application number
BR112014019672A
Other languages
English (en)
Other versions
BR112014019672A2 (pt
Inventor
Swidorski Jacob
A Meanwell Nicholas
Regueiro-Ren Alicia
Sit Sing-Yuen
Chen Jie
Chen Yan
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48946098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014019672(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Uk No 5 Ltd, Bristol Myers Squibb Co filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of BR112014019672A2 publication Critical patent/BR112014019672A2/pt
Publication of BR112014019672A8 publication Critical patent/BR112014019672A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Abstract

TRITERPENOIDES DE C-3 CICLOALQUENILA COM ATIVIDADE INIBIDORA DE MATURAÇÃO DE HIV. A presente invenção refere-s a compostos tendo propriedades de fármaco e bioefetoras, suas composições farmacêuticas e métodos de uso são mencionados. Em particular, triterpenoides de C-3 cicloalquenila que possuem única atividade antiviral são fornecidos como inibidores de maturação de HIV, como representado pelos compostos de fórmulas I, II, III e IV; e em que X pode ser um anel C4-8 cicloalquila, C4-8 cicloalquenila, C4-9 espirocicloalquila, C4-9 espirocicloalquenila, C4-8 oxacicloalquila, C4-8 dioxacicloalquila, C6-8 oxacicloalquenila, C6-8 dioxacicloalquenila, C6-9 oxaespirocicloalquila, ou C6-9 oxaspirocicloalquenila. Estes compostos são úteis para o tratamento de HIV e AIDS.
BR112014019672A 2012-02-15 2013-02-13 Triterpenoides de c-3 cicloalquenila com atividade inibidora de maturação de hiv BR112014019672A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261599040P 2012-02-15 2012-02-15
US13/760,726 US8906889B2 (en) 2012-02-15 2013-02-06 C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
PCT/US2013/025897 WO2013123019A1 (en) 2012-02-15 2013-02-13 C-3 cycloalkenyl triterpenoids with hiv maturation inhibitory activity

Publications (2)

Publication Number Publication Date
BR112014019672A2 BR112014019672A2 (pt) 2017-06-20
BR112014019672A8 true BR112014019672A8 (pt) 2017-07-11

Family

ID=48946098

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014019672A BR112014019672A8 (pt) 2012-02-15 2013-02-13 Triterpenoides de c-3 cicloalquenila com atividade inibidora de maturação de hiv

Country Status (26)

Country Link
US (1) US8906889B2 (pt)
EP (1) EP2814834B1 (pt)
JP (1) JP6155285B2 (pt)
KR (1) KR20140123584A (pt)
CN (2) CN104220451B (pt)
AR (1) AR089996A1 (pt)
AU (1) AU2013221725B2 (pt)
BR (1) BR112014019672A8 (pt)
CA (1) CA2864656A1 (pt)
CL (1) CL2014002141A1 (pt)
CO (1) CO7061077A2 (pt)
EA (1) EA024361B1 (pt)
ES (1) ES2656984T3 (pt)
HK (1) HK1204608A1 (pt)
IL (1) IL234077A (pt)
MX (1) MX2014009235A (pt)
MY (1) MY166793A (pt)
NZ (1) NZ631408A (pt)
PE (1) PE20142315A1 (pt)
PH (1) PH12014501816A1 (pt)
PT (1) PT2814834T (pt)
SG (1) SG11201404748XA (pt)
TW (1) TW201336863A (pt)
UY (1) UY34627A (pt)
WO (1) WO2013123019A1 (pt)
ZA (1) ZA201406724B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
EP2953960A1 (en) 2013-02-06 2015-12-16 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
MA39374A1 (fr) * 2014-04-11 2018-06-29 Viiv Healthcare Uk No 4 Ltd Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
RU2017118572A (ru) * 2014-11-14 2018-12-14 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД Удлиненные аналоги бетулиновой кислоты
EP3218387A1 (en) 2014-11-14 2017-09-20 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
RU2017118576A (ru) 2014-11-14 2018-12-14 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД C-17-арил-замещённые аналоги бетулиновой кислоты
US10221208B2 (en) * 2015-04-14 2019-03-05 ViiV Healthcare UK (No.4) Limited Methods of producing an HIV maturation inhibitor
WO2017017609A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
JP2018521107A (ja) 2015-07-28 2018-08-02 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ感染を予防または治療するためのベツイン誘導体
KR20180054826A (ko) 2015-09-24 2018-05-24 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 성숙 억제 활성을 갖는 화합물
WO2017125870A1 (en) * 2016-01-20 2017-07-27 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
CN106905264B (zh) * 2017-04-12 2019-06-07 连云港杰瑞药业有限公司 一种合成阿扎拉韦中间体的方法
EP3681507B8 (en) * 2017-09-13 2024-03-13 Emmyon, Inc. Ursolic acid morpholine and diethanolamine salts
JP7436385B2 (ja) 2018-04-24 2024-02-21 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド Ｈｉｖ成熟阻害活性を有する化合物
CN109705189B (zh) * 2018-12-29 2020-06-05 中国医学科学院药用植物研究所 具有式i所示结构的三萜衍生物及其制备方法和应用
US20220177439A1 (en) 2019-02-11 2022-06-09 Hetero Labs Limited Novel triterpene derivatives as hiv inhibitors
WO2020229398A1 (de) 2019-05-14 2020-11-19 Bayer Aktiengesellschaft (1-alkenyl)-substituierte pyrazole und triazole als schädlingsbekämpfungsmittel

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050239748A1 (en) 2004-03-17 2005-10-27 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
US20090062243A1 (en) 2007-08-03 2009-03-05 Advanced Life Sciences, Inc. Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof
JP2011508748A (ja) * 2008-01-03 2011-03-17 バイロケム ファーマ インコーポレイテッド 新規のルパン誘導体
CA2714049A1 (en) * 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
CN102858767B (zh) 2009-12-17 2015-08-19 默沙东公司 作为syk抑制剂的氨基嘧啶
WO2011153315A1 (en) * 2010-06-04 2011-12-08 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
EP2576586B1 (en) 2010-06-04 2015-08-12 Bristol-Myers Squibb Company C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors
CA2802308C (en) 2010-07-02 2018-08-28 Lianhong Xu Napht-2-ylacetic acid derivatives to treat aids
DK2670764T3 (en) 2011-01-31 2015-12-07 Bristol Myers Squibb Co C-28 AMINES OF MODIFIED C-3-BETULIN ACID DERIVATIVES AS ANTI-HUMIDITY INHIBITORS
BR112013019419A2 (pt) * 2011-01-31 2019-12-03 Bristol-Myers Squibb Company triterpenoides modificados por c-17 e c-3 com atividade inibitória de maturação de hiv
AU2012312485B2 (en) * 2011-09-21 2016-09-01 VIIV Healthcare UK (No.5) Limited Novel betulinic acid derivatives with antiviral activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
EP2953960A1 (en) * 2013-02-06 2015-12-16 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity

Also Published As

Publication number Publication date
JP2015510515A (ja) 2015-04-09
EA201491531A1 (ru) 2014-11-28
TW201336863A (zh) 2013-09-16
UY34627A (es) 2013-09-02
PT2814834T (pt) 2017-12-06
AR089996A1 (es) 2014-10-01
ES2656984T3 (es) 2018-03-01
BR112014019672A2 (pt) 2017-06-20
CO7061077A2 (es) 2014-09-19
AU2013221725B2 (en) 2016-10-27
US20130210787A1 (en) 2013-08-15
CA2864656A1 (en) 2013-08-22
SG11201404748XA (en) 2014-09-26
CN104220451A (zh) 2014-12-17
NZ631408A (en) 2015-06-26
MY166793A (en) 2018-07-23
AU2013221725A1 (en) 2014-10-02
CN104220451B (zh) 2016-06-29
WO2013123019A1 (en) 2013-08-22
ZA201406724B (en) 2016-08-31
HK1204608A1 (en) 2015-11-27
IL234077A0 (en) 2014-09-30
PE20142315A1 (es) 2015-01-16
EP2814834A1 (en) 2014-12-24
US8906889B2 (en) 2014-12-09
EA024361B1 (ru) 2016-09-30
IL234077A (en) 2016-11-30
KR20140123584A (ko) 2014-10-22
CL2014002141A1 (es) 2014-10-03
CN106046106A (zh) 2016-10-26
EP2814834B1 (en) 2017-09-13
PH12014501816A1 (en) 2014-11-17
MX2014009235A (es) 2014-11-10
JP6155285B2 (ja) 2017-06-28

Similar Documents

Publication Publication Date Title
BR112014019672A8 (pt) Triterpenoides de c-3 cicloalquenila com atividade inibidora de maturação de hiv
BR112014027669A2 (pt) aminas bicíclicas c-17 de triterpenoides com atividade inibidora de maturação de hiv
BR112012030810A2 (pt) "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
CO2017011851A2 (es) Compuestos novedosos
TN2013000321A1 (en) C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
BR112016024545A2 (pt) derivados de pirazolo pirimidina e seu uso como inibidores de malt1
NI201300073A (es) Compuestos y composiciones como inhibidores de la trk
PE20151423A1 (es) Derivados tetrahidropiranilo inhibidores del hcv
BR112013003864A2 (pt) compostos de pirrolpirimidina e usos dos mesmos
BR112015005168A2 (pt) Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos
CO6270324A2 (es) Derivados de pirimidina para el tratamiento del asma epoc rinitis conjutivitis alergica dermatitis atopica cancer hepatitis b hepatitis c vih vph infecciones bacterianas y dermatosis
BR112012007234A2 (pt) combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação
BR112012030818A2 (pt) "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
BR112014006559A2 (pt) derivados do ácido betulínico com atividade antiviral
ECSP15006871A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
MY189483A (en) Purinone derivative
MX2015010003A (es) Triterpenoides c-19 modificados, con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
EA201590862A1 (ru) Фармацевтические композиции
BR112015013124A2 (pt) novos derivados de piridina
PH12016501951B1 (en) Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent
DOP2012000250A (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
BR112014008616A2 (pt) compostos antivirais
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: VIIV HEALTHCARE UK (NO.5) LIMITED (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements